Boston Scientific Corp. (BSX) 5.98 0.035

Boston Scientific Corp.
(BSX) 5.98 0.035

Last Trade:	5.965	Day Range:	5.96 - 6.07
Trade Time:	11:02AM	52wk Range:	5.01 - 7.96
Prev. Close:	5.93	Market Cap:	8.84B
Open:	6.07	Div Yield:	0
Volume:	3505521	PE:
EPS:	0.29

The Latest On BSX

Boston Scientific WallFlex Enteral Stents Shown To Be Safe and Effective in Three Clinical Registries 2/7/12 8:30am

Boston Scientific Announces Global Launch of Expect 19 Flex Endoscopic Ultrasound Aspiration Needle 2/6/12 8:31am

Benzinga's M&A Chatter for Friday February 3, 2012 2/3/12 5:50pm

Financial Breakfast: Morning News Summary for February 2, 2012 2/2/12 7:27am

Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2/1/12 8:32am

Top Performing Health Care Stocks in January 2/1/12 6:32am

Earnings Expectations for the Week of January 30 1/29/12 9:53am

Boston Scientific Announces Favorable Ruling in Patent Infringement Case 1/23/12 8:31am

Piper Jaffray Gives Insight to Medical Technology Industry Overview 1/17/12 9:48am

From Earlier: Boston Scientific Epic Stent Demonstrates Positive Clinical Outcomes in Orion Trial 1/17/12 7:10am

Notable Call Options Activity in Boston Scientific 1/10/12 3:42pm

Boston Scientific's Alair Bronchial Thermoplasty System Achieves Important Reimbursement Milestones 1/4/12 7:33am

Boston Scientific WallFlex Enteral Stents Shown To Be Safe and Effective in Three Clinical Registries 2/7/12

Boston Scientific Announces Global Launch of Expect 19 Flex Endoscopic Ultrasound Aspiration Needle 2/6/12

Benzinga's M&A Chatter for Friday February 3, 2012 2/3/12

Financial Breakfast: Morning News Summary for February 2, 2012 2/2/12

Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2/1/12

Top Performing Health Care Stocks in January 2/1/12

Earnings Expectations for the Week of January 30 1/29/12

Boston Scientific Announces Favorable Ruling in Patent Infringement Case 1/23/12

Piper Jaffray Gives Insight to Medical Technology Industry Overview 1/17/12

From Earlier: Boston Scientific Epic Stent Demonstrates Positive Clinical Outcomes in Orion Trial 1/17/12

Notable Call Options Activity in Boston Scientific 1/10/12

Boston Scientific's Alair Bronchial Thermoplasty System Achieves Important Reimbursement Milestones 1/4/12

Benzinga's M&A Chatter for Friday February 3, 2012 2/3/12

Financial Breakfast: Morning News Summary for February 2, 2012 2/2/12

Top Performing Health Care Stocks in January 2/1/12

Earnings Expectations for the Week of January 30 1/29/12

Cooper Companies Earnings Preview: Double-Digit Revenue Growth Expected 12/7/11

Seven Stocks Insiders Are Buying 12/2/11

Boston Scientific Gets FDA Nod for Long-Lasting Implantable Cardiac Devices 11/30/11

Medtronic Earnings Preview: Analysts Expect Flat EPS, Rising Revenue 11/17/11

Is Boston Scientific a Lucrative Pharma Investment? 10/21/11

Earnings Preview: Analysts Expect Boston Scientific's Revenue, Earnings to Dip 10/19/11

The Best of the Best From the Value Investing Congress 10/19/11

Leon Cooperman's Top Ideas 10/18/11

Financial Breakfast: Morning News Summary for February 2, 2012 2/2/12

Piper Jaffray Gives Insight to Medical Technology Industry Overview 1/17/12

Benzinga's Top Downgrades 12/22/11

Mizuho Downgrades Boston Scientific to Neutral 12/22/11

Stifel Nicolaus Reiterates Buy, $8 Target on Boston Scientific, Raises Estimates 11/23/11

UPDATE: Citi Lowers PT to $5.70 on Boston Scientific 11/23/11

Jefferies Maintains Hold Rating and $6.50 PT on Boston Scientific 11/23/11

Goldman Sachs Maintains Neutral Rating and $5.80 PT on Boston Scientific 11/23/11

Citigroup Lowers PT on Boston Scientific to $5.70 11/23/11

Morgan Stanley Reiterates Equal-Weight on Boston Scientific 11/23/11

Bank of America Maintains Neutral Rating and $8.50 PT on Boston Scientific 11/23/11

Brean Murray Carret & Co Maintains Hold Rating on Boston Scientific 11/23/11

Trade BSX
NOW!

Partner Headlines

2 Comeback Corporate Bonds 2/6/12

Earnings Scorecard: St. Jude - Analyst Blog 2/3/12

The Zacks Analyst Blog Highlights: Medtronic, Edwards Lifesciences, Boston Scientific, St Jude Medical and Southwest Airlines - Press Releases 2/3/12

AngioDynamics to Buy Navilyst - Analyst Blog 2/2/12

Positive Outcome on MDT's CoreValve - Analyst Blog 2/2/12

BSX Disappoints, Guidance Weak - Ahead of Wall Street 2/2/12

Boston Scientific Earnings Down 53%; Sales Fall 8% 2/2/12

Bard Tops in 4Q, Charges Crimp Net - Analyst Blog 2/1/12

Zimmer Holdings Still Struggling To Grow (ZMH, SYK, BSX, ABT) 1/31/12

Edward Owens' Vanguard Health Care Fund Biggest Buys in Fourth Quarter 1/30/12

Earnings Preview: C.R. Bard - Analyst Blog 1/30/12

Earnings Preview: Boston Scientific - Analyst Blog 1/30/12

Press Releases

Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries 2/8/12 Newswire Story

Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference 2/7/12 Newswire Story

Boston Scientific WallFlex® Enteral Stents Shown To Be Safe and Effective in Three Clinical Registries 2/7/12 Newswire Story

Boston Scientific Announces Global Launch of Expect™ 19 Flex Endoscopic Ultrasound Aspiration Needle 2/6/12 Newswire Story

Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2011 2/2/12 Newswire Story

Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe 2/1/12 Newswire Story

Boston Scientific Announces Favorable Ruling in Patent Infringement Case 1/23/12 Newswire Story

Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2011 Financial Results 1/20/12 Newswire Story

Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial 1/16/12 Newswire Story

Boston Scientific Raises Awareness of Heart Disease at Brandon Jennings Invitational 1/5/12 Newswire Story

Boston Scientific's Alair® Bronchial Thermoplasty System Achieves Important Reimbursement Milestones 1/4/12 Newswire Story

NOK, SIRI, BAC, and BSX Can Wait, Buy this Nasdaq Pharmaceutical Stock, Reports Thestockfather.com 12/14/11 Emailwire Story

Get the latest BSX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Boston Scientific Corp. stock price.

Boston Scientific Corp. by YCharts

Boston Scientific Corp. (BSX) 5.98 0.035

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On BSX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social